DEPARTMENT OF PSYCHIATRY
Office of the Chair - Week of March 19 - 23, 2012

Website: http://www.hsc.usf.edu/PSYCH/

Newsletter

Meetings

Tuesday 03/20/12 12:00 noon  No Grand Rounds

Thursday 03/22/12 8:00 a.m.  Call Center Meeting

Resident Lectures:
8:00 a.m.  PGY-1, PGY-2, PGY-3, PGY-4 – Clinical Practice Exercise
9:00 a.m.  CHILD – “Interpersonal Psychotherapy – Grief”  
Dr. Saundra Stock
10:00 a.m.  CHILD – “Interpersonal Psychotherapy – Role Disputes”  
Dr. Saundra Stock
1:00 p.m.  GERI – “Administrative Aspects of Geri-psych”  
Dr. Asher Gorelick

Friday 03/23/12  Third Year Medical Student Lectures:
7:30 a.m.  “Neurology Exam Review” Dr. Rossitza Chichkova
9:00 a.m.  “Psychiatry Review” Dr. Glenn Catalano
11:00 a.m.  “Eating Disorders” Dr. Pauline Powers
1:00 p.m.  “Multiple Sclerosis” Dr. Stanley Krolczyk
2:00 p.m.  “Movement Disorders” Dr. Juan Sanchez-Ramos
3:00 p.m.  “Anxiety Disorders” Dr. Jennifer White

Happy Birthday Wishes to Patti Lowery/March 19th and Lucy Hou/March 19th.

The Department of Psychiatry and Neurosciences is delighted to have the following physicians join us on July 1, 2012:

- Nasreen Akbar received her Bachelor of Arts in Philosophy from Northwestern University in Evanston, IL. She received her medical degree from the Medical College of Georgia School of Medicine.
• Suki Conrad received her Bachelor of Science in Molecular and Microbiology from the University of Central Florida. She will receive her medical degree from the University of South Florida.

• Caroline Cruz received her Bachelor of Science in Microbiology and Cell Science from the University of Florida. She will receive her medical degree from Jefferson Medical College of Thomas Jefferson University in Philadelphia, PA. Caroline received the Howard Hughes Medical Institute Undergraduate Research Award in 2007.

• Caroline De Oleo received her medical degree from the Instituto Tecnologico de Santo Domingo (Intec) in the Dominican Republic.

• Daniel Garay received his Bachelor of Arts in Psychology from the University of Miami. He will receive his medical degree from the Universidad Central del Caribe School of Medicine in Bayamon, PR.

• Heidi Lahteenmaa received her Bachelor of Science degree in Natural Sciences and biological Sciences from the University of Alaska Anchorage. She will receive her Doctor of Osteopathic Medicine degree from Touro University Nevada College of Osteopathic Medicine.

• Ryan Smitherman received his Bachelor of Science in Business Studies from the University of Tennessee. He will receive his medical degree from the University of Tennessee, College of Medicine.

• Gregory Sullivan received his Bachelor of Arts in Biology and Psychology from Hendrix College in Conway, Arkansas and he will receive his Medical degree from the University of Arkansas for Medical Sciences College of Medicine.

New Fellows:
Addiction Psychiatry
• Derek Robben, M.D. - USF Psychiatry Graduating Resident

Child and Adolescent Psychiatry
• Sabrina Caceres, D.O. - USF Psychiatry Graduating Resident
• Zishan Khan, M.D. - From the University of Kansas, School of Medicine, Psychiatry Residency
• Demian Obregon, M.D. - USF Psychiatry Graduating Resident

Geriatric Psychiatry
• David Dada, M.D. - From Columbia University, Harlem Hospital Center Psychiatry Residency, NY

For information regarding the USF Memory Disorders Clinic, please click on the following link:  http://health.usf.edu/medicine/psychiatry/p_memory_disorders_clinic.htm

Research Happenings!

Current Open Studies – Call 813-974-2832 or 813-974-1404 for more information on any study or to refer a patient.
Now Open and Enrolling – ADHD Aggression Study
Kids between ages of 6-12 years old and in generally good health with a diagnosis of ADHD are eligible to participate in a 10-week investigational medication trial. They must be receiving stimulant medication treatment for ADHD symptoms for 1 month prior to study enrollment and be experiencing aggressive behaviors. This study is a 10 week investigational medication trial that will test the effectiveness and safety of molindone hydrochloride extended release as an add-on treatment for aggressive behaviors in children with ADHD. Principal Investigator – Mike Bengtson, MD.

Bipolar I in Teens
This study is a 3-week investigational medication trial that will test the effectiveness and safety of asenapine compared to placebo in teens ages 12-17 with Bipolar I disorder experiencing a manic or mixed episode. A 26-week extension study is available. Study medication, study visits, and required laboratory work provided at no cost. Volunteers must be between the ages of 12-17 years old and in generally good health with a diagnosis of Bipolar I disorder and currently experiencing manic or mixed symptoms. Principal Investigator – Mike Bengtson, MD.

Now Enrolling - Major Depression - Mixed
A 6-week double-blind study comparing lurasidone to placebo in patients with major depression who are also experiencing some hypomanic symptoms. A 12-week open-label extension study is available. This study is looking at patient who may meet proposed DSM-V criteria for Major Depression – Mixed. PI – Carlos Santana, MD

Now Enrolling – Bipolar
A 9-month outpatient study of Ramelteon sub-lingual as an adjunctive treatment to prevent relapse of manic/mixed/depressive symptoms in patients 18-75 years who have experienced a manic/mixed/depressed episode within the last 9 months. Patients will continue on current mood stabilizers, antidepressants, or antipsychotic medications throughout the trial. PI – Carlos Santana, MD

Now Enrolling – Bipolar I Disorder with Depressive Symptoms
An 8-week outpatient study assessing Ramelteon sub-lingual as an adjunctive treatment for patients 18-75 years who are currently experiencing depressive symptoms associated with Bipolar I Disorder. Patients must be on Lithium and/or Depakote. PI – Carlos Santana, MD

Now Enrolling – Schizophrenia Long-Acting IM Depot Open-label Study
An open-label naturalistic study of Aripiprazole IM (long-acting depot) in patients with schizophrenia 18-65 years. Patients must have been prescribed antipsychotic medication for at least 7 months prior to enrollment and have had at least 1 Inpatient Hospitalization in the past 24 months. PI – Carlos Santana, MD

http://health.usf.edu/medicine/psychiatry/research/index.htm

Quality of Life in Youth with Tic Disorders
A one-time study visit evaluating the quality of life in youth with tic disorders, specifically on various aspects of family functioning and the daily challenges faced by children and their families. Children ages 6-17 years old with a diagnosis of a tic
disorder (i.e. Chronic tic disorder or Tourette Syndrome) and are experiencing current tics are eligible to participate. This study is a one-time visit that will include questionnaires and assessments. Participants will also have the opportunity to attend a focus group with youth of similar age assessing kinds of help they received and accessibility of services and the difficulties faced by having tics. Please call (727) 767-8230 for more information. Principal Investigator: Tanya Murphy, MD

Child and Adolescent Tourette’s Disorder Guanfacine Clinical Trial
The purpose of this research study is to learn more about the new extended release formula of the drug, guanfacine. This new formula is called Intuniv. This study will help us understand how safe and how well this new extended release formula of guanfacine works for children with chronic tics. Your child is being asked to take part in this research study because he/she has been diagnosed with Chronic Motor or Vocal Tic Disorder or Tourette’s Disorder. Main symptoms are motor tics such as uncontrolled movements and/or vocal tics such as repeated noises. These tics occur many times a day, nearly every day lasting for at least 1 year. Children ages 6-17 years old are eligible to participate. Please call (727) 767-8230 for more information. Principal Investigator: Tanya Murphy, MD

Living with Tics: The Living with Tics research study hopes to show how well a type of psychotherapy helps children better cope with tics and become more resilient. Children who are interested to participate must attend an initial assessment to determine eligibility. Eligible participants must be between 8 and 18 years of age, have a diagnosis of Tourette Syndrome or Chronic Tic Disorder, experience tic-related impairment, and either be medication-free or on stable medication. If eligible, interested participants will be randomly assigned to receive immediate psychotherapy or a 10 week waitlist control condition followed by subsequent psychotherapy. As part of the study, there is no charge for the psychotherapy treatment. The immediate psychotherapy condition consists of weekly therapy sessions over a 10 week period. This multi-component treatment approach includes habit reversal training, anger management, problem solving skills and other related therapeutic components to help improve the quality of life for children with chronic tic disorders. Please call (727) 767-8230 for more information. Principal Investigator: Eric Storch PhD.

Adult OCD Ondansetron Clinical Trial
The purpose of this research study is to investigate the effectiveness, safety, and tolerability of 2 dosages Ondansetron as compared to placebo (a substance which looks like an active drug but has no active ingredient) in adult who have OCD and who are currently taking a selective serotonin reuptake inhibitor (SRI) such as Anafranil® (clomipramine) Paxil® (paroxetine), Prozac® (fluoxetine), Luvox® (fluvoxamine, or Zoloft® (sertraline). Another purpose of this study is to find out how the study drug works in the body when taken along with an SSRI. Please call (727) 767-8230 for more information. Principal Investigator: Tanya Murphy, MD
**Pediatric OCD D-Cycloserine and Cognitive Behavioral Therapy (CBT) Research Study**

The purpose of this research study is to examine if d-cycloserine enhances cognitive behavioral therapy for pediatric OCD. Participants will be involved in fifteen clinical visits spanning a nine-month period. Each participant will receive ten sessions of cognitive behavioral therapy and seven doses of the study medication or placebo one hour prior to session. Children ages 7-17 years old are eligible to participate. Please call (727) 767-8230 for more information.

Principal Investigator: Eric Storch PhD

---

**Cognitive-Behavioral Therapy (CBT) for Anxiety Disorders in Children with Autism Spectrum Disorder Research Study**

The purpose of this research study is to examine the efficacy of a manualized cognitive-behavioral therapy to treat anxiety disorders in children with autism spectrum disorders. Therapy sessions last approximately one hour a week for sixteen weeks. In addition, participants will be involved in a number of anxiety and developmental assessments free of charge. Children ages 7-16 years old are eligible to participate. Please call (727) 767-8230 for more information. Principal Investigator: Eric Storch PhD